Articles

Karyopharm's Selinexor Plus Ruxolitinib SENTRY Trial Data to be Presented at EHA 2026

Karyopharm's Phase 3 SENTRY trial evaluating selinexor in combination with ruxolitinib for myelofibrosis has been selected for a late-breaking oral presentation at EHA 2026. This presentation will feature results from the randomized, double-blind, placebo-controlled study.

EMA's CHMP Recommends Oral Wegovy Approval, Expanding Obesity Treatment Options in Europe

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of an oral formulation of Wegovy for weight management. This recommendation signifies a crucial step towards increased accessibility of GLP-1 receptor agonist therapies for obesity in Europe.

FDA Approves AstraZeneca's Imfinzi-BCG Combination for High-Risk NMIBC

The FDA has approved AstraZeneca's Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). This marks the first immunotherapy-based combination therapy approved for this indication.

ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study

Structured plan for ASCO26: Summit, Akeso claim OS victory for ivonescimab in pivotal Chinese study

Medscape's AI Integration in Hematology: A Catalyst for Change at EHA 2026

Medscape is bringing AI to the forefront of hematology discussions at EHA 2026, signaling a significant shift in how clinical data and treatment options will be accessed and utilized. This move is poised to influence oncology research and clinical practice, presenting new opportunities and challenges for the pharmaceutical industry.

OS Therapies Publishes Four Articles on OST-HER2 and Osteosarcoma, Signaling Clinical Progress

OS Therapies has announced the publication of four articles focusing on its lead asset OST-HER2 and osteosarcoma in Drug Discovery World. This news coincides with the company's upcoming presentation of Phase 2b clinical trial data at the ASCO Annual Meeting and its plans for a BLA filing.

EMA celebrates diversity and inclusion in science and healthcare

Structured plan for EMA celebrates diversity and inclusion in science and healthcare

Navigating the Future of GMP: Reliance, Annex 1, and AI

The pharmaceutical industry is at a crossroads, with evolving regulatory landscapes and emerging technologies like AI demanding a modernization of Good Manufacturing Practices (GMP). This article examines the impact of increased regulatory reliance, the implementation of EU GMP Annex 1, and the integration of Artificial Intelligence on future compliance strategies.

Arrowhead Pharmaceuticals to Participate in Key June 2026 Industry Events

Arrowhead Pharmaceuticals is set to participate in several key industry events throughout June 2026. These appearances provide a crucial opportunity for analysts, strategy, and business development teams to gain insights into the company's pipeline advancements and strategic direction.

BioCryst Presents New HAE Data for ORLADEYO® and Navenibart at EAACI 2026

BioCryst Pharmaceuticals will present new hereditary angioedema (HAE) data for its oral therapy ORLADEYO® (berotralstat) and its investigational therapy navenibart at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting. This presentation highlights BioCryst's ongoing commitment to advancing HAE treatment and understanding.

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Structured plan for Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

European Commission Opens 2026 Joint Scientific Consultation Submission Window

The European Commission has announced the opening of the third 2026 submission window for Joint Scientific Consultations (JSCs), a critical step for health technology developers under the new EU HTA Regulation. This provides an opportunity for early alignment with EU HTA bodies.

HER2 Biology: Driving Next-Generation Cancer Therapies

Understanding HER2 biology is crucial for developing next-generation cancer treatments. This article explores how advancements in targeting HER2 are leading to more effective and personalized therapies.

Eisai's Leqembi Sales Forecast: Projecting Blockbuster Status in Alzheimer's

Eisai projects significant growth for its Alzheimer's treatment, Leqembi, with sales forecasts indicating a strong path toward blockbuster status. This analysis explores the drivers behind this projection and its strategic implications for the pharmaceutical industry.

UCB's Bimzelx vs. AbbVie's Skyrizi: Psoriatic Arthritis Competitive Landscape

UCB's Bimzelx has demonstrated a competitive advantage over AbbVie's Skyrizi in head-to-head psoriatic arthritis trials. This analysis explores the implications for the competitive landscape and pharmaceutical business development.

ImmunityBio's Anktiva Expansion: Navigating FDA Decision Dates and Regulatory Hurdles

ImmunityBio is navigating a complex regulatory landscape for its bladder cancer therapy, Anktiva. This article provides insights into upcoming FDA decisions and their impact on the pharmaceutical industry.

About Us: Your Partner in Pharmaceutical Innovation

Learn about our mission, vision, and values as a leader in the pharmaceutical industry. We strive to foster innovation and collaboration for better healthcare.

AstraZeneca's Imfinzi and Imjudo: A Breakthrough in Liver Cancer Treatment

AstraZeneca's Imfinzi and Imjudo have shown promising results in early-stage liver cancer at ASCO. This article explores the implications for the pharmaceutical industry.

Why Direct-to-Patient is the Future of Pharma Access

The shift towards direct-to-patient models is reshaping pharmaceutical access. This article explores the implications for pharma teams and the industry at large.

Revolution Medicines' RAS Leadership at ASCO: Insights and Implications

Revolution Medicines showcased its confidence in RAS leadership at ASCO, amidst rising competition. This article explores the implications for the pharma landscape.